Skip to content

Assessment of Clinically Related Outcomes and Biomarker Analysis for Translational Integration in Colorectal Cancer

Prospective, Population-based Cohort Collection of Blood Samples and Tumor Tissue From Patients Operated on for Primary or Metastatic Colorectal Cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01762813
Acronym
ACROBATICC
Enrollment
1200
Registered
2013-01-08
Start date
2013-01-01
Completion date
2036-12-31
Last updated
2026-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Keywords

Colon cancer, rectal cancer, liver metastasis, survival, biomarker, molecular profile

Brief summary

* A prospective, observational study on clinical outcomes of surgical management of primary and metastatic colorectal cancer * Prospective collection of tissues to explore potential biomarkers in blood and/or primary or secondary cancers and/or normal colon

Detailed description

Prospective project in collecting and assessing clinical outcomes data related to molecular profiling of tumors based on cancer primary or metastatic tissue or tissue from peripheral blood samples. As a future part of the project will be collected patient reported outcomes (PROs) for assessing clinical outcomes in relation to clinical pathways, patient reported results, as well as tumor profiling by molecular methods.

Interventions

PROCEDUREopen and laparoscopic surgery

Curative surgery for either primary (colorectal cancer, crc) or metastatic CRC (liver surgery)

Sponsors

Helse Stavanger HF
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of colorectal cancer, primary or metastatic (liver), with a treatment intention of planned curative surgery * Informed consent to participate * Age ≥18

Exclusion criteria

* failure to provide written informed consent

Design outcomes

Primary

MeasureTime frameDescription
Cancer-specific survival5-yearsTime from surgery to death of cancer

Secondary

MeasureTime frameDescription
Recurrence-free survival3 and 5 yearsTime from surgery to recurrence of cancer

Countries

Norway

Contacts

CONTACTRamesh L. Kajavi, RN
acro.gitan@gmail.com92297672
CONTACTMarina Alexeeva, PhD
marina.alexeeva@sus.no
PRINCIPAL_INVESTIGATORKjetil Søreide, MD, PhD, FRCS, FACS

Helse Stavanger HF

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 1, 2026